Abstract
6591 Background: Carmustine, etoposide, ARA-C, melphalan (BEAM) and carmustine, cyclophosphamide, etoposide (CBV) are commonly used high-dose chemotherapy regimens prior to autologous transplantation in patients of non-Hodgkin’s (NHL) and Hodgkin’s lymphoma (HL) but are associated with significant toxicity. We report the results of lomustine, ARA-C, cyclophosphamide, etoposide (LACE) regimen from our center and role of prognostic factors. Methods: Forty-two patients of relapsed and refractory NHL (14) and HD (28) who received LACE-regimen between November 2007- December 2010 were included in this retrospective study. LACE-regimen included lomustine-200 mg/m2 d-7, etoposide 1000mg/m2 d-7, ARA-C 2000 mg/m2 d-6, d-5 and cyclophosphamide 1,800mg/m2 d-4 to d-2. PET-CT was done pretransplant, on day 100 and at 1 year post transplant. Prognostic factors evaluated for overall survival (OS) and progression-free survival (PFS) included time between diagnosis - transplant, time between diagnosis - first relapse, PET...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
